Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ly Hoang Roberts

Urogynecology and Reconstructive Pelvic Surgery Cleveland, OH Medical Doctor

NPI 1689051674 CMS profile 8611149

9500 Euclid Ave, Cleveland, OH 44195

Open in the dashboard

General payments

$23,220

71 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ly Hoang Roberts of Cleveland, OH is reported in the CMS Open Payments database as having received $23,220 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,196 18
2024 General $6,747 24
2023 General $1,279 14
2022 General $614 7
2021 General $10,146 3
2020 General $239 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ly Hoang Roberts
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Ly Hoang Roberts were reported at $4,196. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Ly Hoang Roberts Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $799 $319–$2,013 $163
2020 $239 $384 $158–$1,360 $114
2021 $10,146 $641 $247–$2,515 $132
2022 $614 $843 $347–$2,794 $149
2023 $1,279 $819 $308–$2,302 $160
2024 $6,747 $882 $306–$2,459 $164
2025 $4,196 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $21,361 47 payments
  2. Intuitive Surgical, Inc. $841 5 payments
  3. Axonics Modulation Technologies, Inc. $259 5 payments
  4. Boston Scientific Corporation $239 7 payments
  5. Astellas Pharma US Inc $183 2 payments
  6. Urovant Sciences Inc $125 2 payments
  7. Genzyme Corporation $117 1 payment
  8. Stryker Corporation $50 1 payment
  9. Cook Medical LLC $45 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $10,000 1 payment
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,293 3 payments
  3. Food and Beverage $3,947 61 payments
  4. Travel and Lodging $797 4 payments
  5. Education $183 2 payments
Products named General payments · program years 2020–2025
  1. INTERSTIM $21,225 46 payments
  2. Da Vinci Surgical System $841 5 payments
  3. Axonics $295 7 payments
  4. Lynx System $158 2 payments
  5. APS $135 1 payment
  6. JEVTANA $117 1 payment
  7. Bulkamid $82 1 payment
  8. SPY TECHNOLOGY $50 1 payment
  9. Cook Medical Urology $45 1 payment
  10. LITHOVUE $18 1 payment
  11. Other $27 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

448

Median for Urology: 1,053

Drug cost

$97,572

Median for Urology: $101,464

Branded share of claims

61.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 88 $49,967
Gemtesa Vibegron Brand 49 $30,815
Mirabegron Er Mirabegron Brand 11 $6,266
Trospium Chloride Generic 49 $2,904
Estradiol Generic 53 $2,778
Trospium Chloride Er Trospium Chloride Brand 25 $2,004
Solifenacin Succinate Generic 20 $1,304
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 31 $581
Oxybutynin Chloride Er Oxybutynin Chloride Brand 28 $461
Cephalexin Generic 36 $212

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$49,010

Medicare's payments for the services billed

Medicare patients

257

Average age 74

Services billed

677

224 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 37%
Chronic kidney disease 33%
Osteoporosis 27%
Diabetes 26%
Cancer 23%
Ischemic heart disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record